| Title |
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
|
|---|---|
| Published in |
HEPAC Health Economics in Prevention and Care, May 2014
|
| DOI | 10.1007/s10198-014-0594-4 |
| Pubmed ID | |
| Authors |
Petra Baji, Márta Péntek, László Czirják, Zoltán Szekanecz, György Nagy, László Gulácsi, Valentin Brodszky |
| Abstract |
The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of rheumatoid arthritis (RA), namely abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 33% |
| Canada | 1 | 11% |
| United Kingdom | 1 | 11% |
| Unknown | 4 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 4 | 44% |
| Members of the public | 3 | 33% |
| Scientists | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 2% |
| United Kingdom | 1 | <1% |
| Unknown | 121 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 29 | 23% |
| Researcher | 20 | 16% |
| Student > Ph. D. Student | 14 | 11% |
| Other | 12 | 10% |
| Student > Bachelor | 9 | 7% |
| Other | 19 | 15% |
| Unknown | 21 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 43% |
| Agricultural and Biological Sciences | 12 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Social Sciences | 4 | 3% |
| Other | 13 | 10% |
| Unknown | 26 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2015.
All research outputs
#6,425,745
of 25,420,980 outputs
Outputs from HEPAC Health Economics in Prevention and Care
#420
of 1,308 outputs
Outputs of similar age
#56,976
of 241,979 outputs
Outputs of similar age from HEPAC Health Economics in Prevention and Care
#8
of 38 outputs
Altmetric has tracked 25,420,980 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,979 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.